-- Health care stocks were flat to lower premarket Monday, with the iShares Biotechnology ETF (IBB) inactive and the State Street Health Care Select Sector SPDR ETF (XLV) down 0.5%.
Indivior Pharmaceuticals (INDV) shares were up more than 3% after the company said it has entered into a $175 million accelerated share repurchase agreement with Barclays Bank, to be executed under the company's existing $400 million buyback program.
Welltower (WELL) has an average rating of buy and mean price target of $234.16, according to analysts polled by FactSet.Price: $215.99, Change: $-1.01, Percent Change: -0.47%
Amgen (AMGN) said Monday it will invest an additional $300 million in its biologics manufacturing facility in Puerto Rico.The Juncos site makes biologic medicines distributed to over 60 countries, the company said.Amgen said that over the past year, it announced planned investments of $650 million in Puerto Rico, $900 million in Ohio, as well as $600 million in a facility in California. Amgen said it has also invested over $1.5 billion in North Carolina.Price: $324.07, Change: $-5.75, Percent Change: -1.74%
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Pinnacle West delivered strong Q1 2026 results with EPS of $0.27 versus a loss of $0.04 in the prior year, driven by Arizona's warmest winter on record and continued economic growth. Operating revenues rose 11.4% to $1,149.6M with 2.2% customer growth and 9.4% weather-normalized retail sales growth, while commercial and industrial sales surged 14.6%. The company demonstrated strong operational execution with O&M expenses declining 7.8% despite expansion, though interest expense increased 22.3% from higher financing costs. PNW maintains 2026 EPS guidance of $4.55-$4.75 while extending long-term sales growth outlook to 5%-7% through 2030. The pending 2025 APS rate case remains a critical catalyst, with PNW seeking a $611M net revenue increase and final decision expected in Q4 2026. We believe successful rate recovery will be essential for earning adequate returns on PNW's $10.35B capital investment plan designed to capture over 20GW of potential demand growth opportunities.